Studies microbes and immunity in people with dermatomyositis and lung disease
Compares microbial communities and immune function in people with anti-MDA5 dermatomyositis.
Plain-language title generated from the registry record
Registry title: Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06203249, who can take part
Where in China
- PLABeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT06203249
- Record updated
- 12 January 2024
- Original description
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.Read full original descriptionShow less
Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Inclusion: Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive; Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD; Must have undergone bronchoalveolar lavage; Age≥18 years old; Patients who signed informed consent forms.
Exclusion: Patients who had other connective tissue diseases; Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors; Pregnant or lactating patients; The patient also participated in any other clinical trial; Disagreement for inclusion in this study.